Phase III Data Back Keryx's Plan To Expand Auryxia Market
This article was originally published in Scrip
Keryx Biopharmaceuticals Inc. had a rough first year of sales for its oral, iron-based phosphate binder Auryxia (ferric citrate), but the company and it investors have high hopes that new Phase III data will support approval for a second indication that could double the drug's market.
You may also be interested in...
Company plans to use the same sales force and broad insurance coverage for oral iron product in new use for CKD patients with iron deficiency anemia not on dialysis, as for the first approved use in dialysis patients, so it will "hit the ground running."
From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.